Pharma giants compete to release the first weight-loss pill
Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that … Read more